Biotech · Public company · San Francisco, CA, US
Nektar Therapeutics
Ticker NKTR · SEC CIK 0000906709
Track this companyFree. Adds Nektar Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials254 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline18
- NKTR-255 at 1.5 µg/kgPhase 3 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- NKTR-255 at 3.0 μg/kgPhase 3 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- NKTR-255 at 3.0/6.0 μg/kgPhase 3 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RezpegaldesleukinPhase 3 · Moderate-to-Severe Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 2 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- LY3471851Phase 2 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- LY3471851Phase 2 · Colitis, UlcerativeClinicalTrials.gov · fetched Nov 12, 2026
- NKTR-255Phase 2 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- RezpegaldesleukinPhase 2 · Alopecia AreataClinicalTrials.gov · fetched Nov 12, 2026
- BempegaldesleukinPhase 1 · Covid-19ClinicalTrials.gov · fetched Nov 12, 2026
- DaratumumabPhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- LevocetirizinePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- LY3471851Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- LY3471851Phase 1 · Dermatitis, AtopicClinicalTrials.gov · fetched Nov 12, 2026
- LY3471851Phase 1 · PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- NKTR-255Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- NKTR-255 Q21Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · RECRUITING · started Aug 7, 2026ClinicalTrials.gov NCT07711418 · fetched Nov 12, 2026
- A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · RECRUITING · started Jun 29, 2026ClinicalTrials.gov NCT07690371 · fetched Nov 12, 2026
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)PHASE2 · COMPLETED · started Apr 2, 2024ClinicalTrials.gov NCT06340360 · fetched Nov 12, 2026
- C-TIL051 in Non-Small Cell Lung CancerPHASE1 · TERMINATED · started Feb 29, 2024ClinicalTrials.gov NCT05676749 · fetched Nov 12, 2026
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 15, 2023ClinicalTrials.gov NCT06136741 · fetched Nov 12, 2026
- NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaPHASE2_PHASE3 · TERMINATED · started Feb 23, 2023ClinicalTrials.gov NCT05664217 · fetched Nov 12, 2026
- REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)PHASE2 · RECRUITING · started Jan 10, 2023ClinicalTrials.gov NCT05632809 · fetched Nov 12, 2026
- NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell LymphomaPHASE1 · COMPLETED · started Dec 8, 2022ClinicalTrials.gov NCT05359211 · fetched Nov 12, 2026
- A Phase I Study of LY3471851 in Healthy ParticipantsPHASE1 · COMPLETED · started Oct 5, 2022ClinicalTrials.gov NCT05565729 · fetched Nov 12, 2026
- A Single-Dose Study of LY3471851 in Healthy ParticipantsPHASE1 · COMPLETED · started Aug 16, 2021ClinicalTrials.gov NCT04998487 · fetched Nov 12, 2026
- Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell CarcinomaPHASE2 · TERMINATED · started Aug 5, 2021ClinicalTrials.gov NCT04936841 · fetched Nov 12, 2026
- A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)PHASE2 · TERMINATED · started Mar 22, 2021ClinicalTrials.gov NCT04677179 · fetched Nov 12, 2026
- A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19PHASE1 · COMPLETED · started Nov 13, 2020ClinicalTrials.gov NCT04646044 · fetched Nov 12, 2026
- Study of NKTR 255 in Combination With Cetuximab in Solid TumorsPHASE1_PHASE2 · COMPLETED · started Oct 30, 2020ClinicalTrials.gov NCT04616196 · fetched Nov 12, 2026
- A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has SpreadPHASE1 · COMPLETED · started Sep 11, 2020ClinicalTrials.gov NCT04540705 · fetched Nov 12, 2026
- A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)PHASE2 · COMPLETED · started Aug 19, 2020ClinicalTrials.gov NCT04433585 · fetched Nov 12, 2026
- A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder CancerPHASE3 · COMPLETED · started Feb 5, 2020ClinicalTrials.gov NCT04209114 · fetched Nov 12, 2026
- A Study of LY3471851 in Participants With EczemaPHASE1 · COMPLETED · started Dec 4, 2019ClinicalTrials.gov NCT04081350 · fetched Nov 12, 2026
- A Study of LY3471851 in Participants With PsoriasisPHASE1 · COMPLETED · started Nov 26, 2019ClinicalTrials.gov NCT04119557 · fetched Nov 12, 2026
- A Study of LY3471851 in Healthy ParticipantsPHASE1 · COMPLETED · started Oct 29, 2019ClinicalTrials.gov NCT04133116 · fetched Nov 12, 2026
- NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaPHASE1 · COMPLETED · started Oct 7, 2019ClinicalTrials.gov NCT04136756 · fetched Nov 12, 2026
- A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaPHASE3 · COMPLETED · started Sep 21, 2018ClinicalTrials.gov NCT03635983 · fetched Nov 12, 2026
- A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)PHASE1 · COMPLETED · started Apr 18, 2018ClinicalTrials.gov NCT03556007 · fetched Nov 12, 2026
- A Study of NKTR-358 (LY3471851) in Healthy ParticipantsPHASE1 · COMPLETED · started Mar 19, 2017ClinicalTrials.gov NCT04380324 · fetched Nov 12, 2026
- Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast CancerPHASE2 · COMPLETED · started Aug 1, 2015ClinicalTrials.gov NCT02312622 · fetched Nov 12, 2026
SEC filings12
- 8-K · CURRENT REPORTSEC EDGAR · filed Oct 1, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Sep 25, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jun 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 20, 2026 · fetched Nov 12, 2026